Our Partners

  • Sucampo Pharmaceuticals, Inc. – our collaboration partner who has purchased an option to acquire an exclusive license to commercialize CPP-1X/sulindac in North America. View press release.
  • Tillotts Pharma AGour exclusive licensing partner for European and Japanese rights to develop and commercialize the combination of CPP-1X/sulindac for the treatment of familial adenomatous polyposis (FAP), an orphan disease, and other gastrointestinal conditions.  View press release.
  • University of Arizona and University of California, Irvinewhere it all started and with whom CPP has an exclusive license agreement for key intellectual property for eflornithine plus sulindac.
  • NMTRC – the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) is a group of 18 universities and children’s hospitals headquartered at the Helen DeVos Children’s Hospital that offer a nationwide network of childhood cancer clinical trials.
  • NANT and the Children’s Hospital of LANew Approaches to Neuroblastoma Therapy is a group of 15 Universities and Children’s Hospitals with strong research and treatment programs for neuroblastoma.
  • NCI/SWOGthe National Cancer Institute (NCI) and Southwest Oncology Group, an NCI-supported clinical trials group.
  • CEPiA Sanofi – our manufacturing partner – Within the Industrial Affairs Division of Sanofi, CEPiA is an organization fully dedicated to third party CMO activities.
  • TRAC – Translational Accelerator, LLC, a venture fund formed to invest in Arizona biotech companies, is the lead investor.
  • Former Biotech and Pharmaceutical executives – featuring Board level executives and commercialization experts.